Lifeboat Foundation

Is aging a natural process that we simply have to accept as a fact of life?

A philosopher would say yes. Many doctors would also agree: that our cells eventually reach a point where they can no longer divide and either die or reach senescence, a retirement phase. Many scientists believe in the “Hayflick limit” — that no one can live past about 120 years old. These people might also say that aging — and dying — is a good thing; that the world is already overcrowded, that we already cannot handle our aging populations, that life must be finite to appreciate it, that all good things must come to an end.

But there’s a growing group of people — including gerontologists, biologists, engineers, and futurists—who believe that aging is a disease in itself, a disease that can be cured. That aging is not an immutable process, an inevitable “dying of the light,” to quote poet Dylan Thomas, but one we can “rage against” — through science, drugs, and lifestyle changes.

Continue reading “What’s Telling About Telomeres (and the Aging Process)” »

Ira Pastor, ideaXme longevity and aging ambassador and founder of Bioquark interviews Luba Greenwood J.D., Strategic Business Development and Corporate Ventures, Verily (Google Life Sciences), Board Member Mass Bio and Brooklyn ImmunoTherapeutics LLC.

Note: Following this interview, Verily announced a major set of collaborations with big pharma companies, further executing on its strategy in healthcare. Breaking news: https://www.cnbc.com/2019/05/20/alphabet-verily-doing-clinic…T4eLzIucEI

Continue reading “Building the Future of Global Health: Big Tech’s Big Ideas” »

Alongside our Ending Age-related Diseases 2019 annual conference, we are proud to announce the launch of a special pre-conference biotech workshop led by Dr. Kelsey Moody, CEO of Ichor Therapeutics, a successful and rapidly growing rejuvenation biotechnology company.

This joint event between the Life Extension Advocacy Foundation and Ichor Therapeutics is an essential workshop where you will learn about the fundamentals of launching and growing a successful biotechnology company with an emphasis on the nuances specific to the emerging rejuvenation biotechnology industry.

Sounds like a more extensive 23andMe, dedicated to anti-ageing.

The role that the gut microbiome plays in aging is increasingly being appreciated in the research world as more evidence arrives to support it. A new publication reviews the various supporting evidence and takes a look at the gut microbiome in the context of nutrient-rich diets and how they facilitate the progression of dysbiosis and disease [1].

What is the microbiome?

The microbiome is the varied community of bacteria, archaea, eukarya, and viruses that inhabit our guts. The four bacterial phyla of Firmicutes, Bacteroidetes, Proteobacteria, and Actinobacteria comprise 98% of the intestinal microbiome.

Continue reading “Nutrient-Rich Diets May Lead to Dysbiosis and Age-Related Diseases” »

As time passes, the number of damaged, ‘senescent’ cells in our bodies increases. These in turn are responsible for many effects of ageing. Now scientists are working to eliminate them.

But while saying that night owls are going to die early makes for an eye-catching headline, the real story isn’t quite that simple.

Despite alarmist headlines and a study that suggested morning people live longer, the truth is more complicated.

Liz intends to take another gene therapy before the end of the year.